presence of varying concentrations of reconstituted HDL (rHDL) in the presence or absence of OVA and OVA-specific immune responses were measured. To assess the effect of HDL on dendritic cell activation and maturation, mouse bone marrow was cultured with GM-CSF to generate dendritic cells (BM-DCs), which were collected, cultured and treated with LPS in the presence or absence of rHDL.

Results OVA-primed LN cells secreted increased levels of IFN- γ and IL-17 that were significantly suppressed in the presence of rHDL in a dose-dependent manner. rHDL was also found to exert a suppressive effect on T cell proliferation as indicated by IL-2 measurement. Finally, rHDL-treated LPS-stimulated BM-DCs did not demonstrate any significant phenotypic differences as assessed by FACS analysis on CD86, CD40 and PDL-1 molecules as compared to control LPS-stimulated BM-DCs.

Conclusions rHDL exerts a direct immunomodulatory function on T cells in vitro by suppressing their proliferation and the expression of inflammatory cytokines. Ongoing work is focused on the delineation of the mechanism involved in the rHDL-mediated suppression of the immune response both in vitro and in vivo. These data identify rHDL as an important player in the homeostatic regulation of the inflammatory response and a potential therapeutic target for chronic inflammatory diseases.

A3.16 SPECIFIC OVEREXPRESSION OF SYNOVIAL INTERLEUKIN-21⁺ CD4⁺ T CELLS CO-EXPRESSING TUMOUR NECROSIS FACTOR IN RHEUMATOID ARTHRITIS: ROLE IN JOINT DESTRUCTION?

doi:10.1136/annrheumdis-2013-203216.16

^{1,2}M Cristina Lebre, ³Pedro L Vieira, ^{1,2}Saida Aarras, ³Thomas Newsom-Davis, ¹Paul P Tak, ³Gavin R Screaton. ¹Division of Clinical Immunology and Rheumatology; ²Department Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; ³Department of Immunology, Imperial College London, Hammersmith Campus, London, UK

Background and Objectives IL-21 is a cytokine produced by activated CD4⁺ T cells and T follicular helper cells (TFh) that has been implicated in several autoimmune diseases. IL-21 regulates antibody production by B cells and induces osteoclastogenesis, mechanisms that contribute to rheumatoid arthritis (RA) pathology. Importantly, IL-21R blockade ameliorates arthritis in mice. Here we investigated the functional characteristics of CD4⁺IL-21⁺ T cells in RA.

Materials and Methods We evaluated the expression of surface markers and cytokine production in matched peripheral blood (PB) and synovial fluid (SF) from 13 RA and 6 psoriatic arthritis (PsA) patients, and PB of 17 healthy control (HC) subjects by flow cytometry following PMA/Ionomycin stimulation ex-vivo. IL-21 concentrations were assessed by ELISA in cell-free SF samples of RA (n = 15), PsA (n = 14) and OA (n = 6) patients and in synovial biopsy culture supernatants (6 days) of RA (n = 6) and ankylosing spondylitis (AS; n = 5) patients. The effects of IL-21 were evaluated on cytokine and matrix metalloproteinase (MMP) release by RA synovial biopsies.

Results The frequency of IL-21+CD4⁺ T cells in RA and PsA SF was significantly higher compared to PB (P < 0.0001 and P < 0.0001, respectively). Moreover, the frequency of both total IL-21+CD4⁺ (P = 0.0140) and IL-21+TNF+CD4⁺ T cells (P = 0.0038) in RA SF were significantly increased compared to PsA patients. The frequency of IL-21+CD4⁺ T cells in RA PB was positively correlated with DAS28 (r = 0.592, P = 0.033), serum anti-cyclic citrullinated peptide (anti-CCP) antibodies (r = 0.788, P = 0.001) and IgM-rheumatoid factor (IgM-RF; r = 0.691, P = 0.009). In addition, the percentage of IL-21+CD4⁺ T cells in anti-CCP+ or IgM-RF+ patients was significantly higher compared to anti-CCP- (P = 0.03) and

IgM-RF- (P = 0.01) patients respectively. In addition to PB and SF, we found IL-21+CD4⁺ T cells present in RA synovial tissue. Significant higher levels of IL-21 in RA SF compared to OA SF (P = 0.04) were observed confirming previous observations. RA synovial biopsies released significantly higher levels of IL-21 compared to biopsies from AS patients. The levels of IL-21 in SF were associated with CRP and with the MMP-1 and MMP-3. Related to this, IL-21 selectively induced MMP-1 and MMP-3 secretion by RA synovial biopsies. Synovial IL-21+CD4⁺ T cells did not phenotypically fit the TFh cell paradigm in that they did not express CXCR5 and ICOS.

Conclusions The results of this study support the notion that IL-21-producing CD4 T cells are involved in promoting synovial inflammation (TNF) and joint destruction (MMP) in RA and might be a therapeutic target in this disease.

A3.17 SYNOVIAL FIBROBLASTS DIRECTLY INDUCE TH17 PATHOGENICITY VIA THE CYCLOOXYGENASE/ PROSTAGLANDIN-E₂ PATHWAY, INDEPENDENT OF IL-23

doi:10.1136/annrheumdis-2013-203216.17

^{1,2}Sandra MJ Paulissen, ^{1,2}Jan Piet van Hamburg, ^{1,2}Nadine Davelaar, ^{1,2}Patrick S Asmawidjaja, ^{1,2}Johanna MW Hazes ¹Erik Lubberts. ¹Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands; ²Department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands

Background Th17 cells are critically involved in autoimmune disease induction and severity. Recently, we showed that Th17 cells, but not Th1 cells, from patients with rheumatoid arthritis (RA) upon interaction with RA-synovial-fibroblasts (RASf) directly induced autocrine IL-17A production. This autocrine IL-17A production in turn creates a pro-inflammatory loop characterised by up-regulation of the pro-inflammatory cytokines IL-6 and IL-8, and the cartilage degrading enzymes MMP-1 and MMP-3. This loop may be an important pathway in the progression of an early inflammatory arthritis, towards a chronic destructive arthritis. However, the mechanism underlying the autocrine IL-17A production in the pro-inflammatory loop upon Th17-RASf interaction is currently unknown.

Objectives To investigate the mechanism responsible for the autocrine IL-17A induction upon Th17-RASf interaction.

Materials and Methods CD4⁺CD45RO⁺CCR6⁺ (Th17) and CD4⁺CD45RO⁺CCR6⁻ (Th1) cells were isolated by FACS sorting from healthy controls and early RA patients. These cells were co-cultured with RASf, in the presence of neutralising antibodies directed against soluble IL-6R (anti-sIL-6R), and/or IL-1 β , and/or IL-23, etanercept, and celecoxib. Gene expression profiles were generated and supernatant was collected for cytokine analyses by ELISA.

Results IL-6, IL-1 β and cyclooxygenase-2 (COX-2) expressions and prostaglandin-E₂ (PGE₂) production in Th17-RASf cultures were higher than in Th1-RASf cultures. Cytokine neutralisation showed that IL-1 β , IL-6 and IL-23 contributed marginally to the IL-17A induction. In contrast, treatment with celecoxib, a COX-2 inhibitor, resulted in significantly lower PGE₂ and IL-17A production. This effect was IL-17A specific as no inhibitory effects were found on IFN- γ and TNF- α production. Combined celecoxib and TNF- α blockade more effectively suppressed the pro-inflammatory loop than did single treatment, as shown by lower IL-6, IL-8, matrix metalloproteinase-1 (MMP-1) and MMP-3 production.

Conclusions These findings show a critical role for the COX-2/PGE₂ pathway in driving Th17-mediated synovial inflammation in an IL-23 and monocyte independent manner. Therefore, it would be important to control PGE₂ in chronic inflammation in RA and other Th17-mediated autoimmune disorders.